Kimberly Chong

Array ( [id] => 12909694 [patent_doc_number] => 20180195073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/849776 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12751222 [patent_doc_number] => 20180142241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA [patent_app_type] => utility [patent_app_number] => 15/849887 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14978299 [patent_doc_number] => 10443055 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer [patent_app_type] => utility [patent_app_number] => 15/845573 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 55 [patent_no_of_words] => 27811 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15845573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15210465 [patent_doc_number] => 20190367919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF STARGARDT DISEASE [patent_app_type] => utility [patent_app_number] => 16/465405 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624981 [patent_doc_number] => 20180100157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/837905 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15837905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12585684 [patent_doc_number] => 20180087057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/834110 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15834110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12814309 [patent_doc_number] => 20180163273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => BREAST CANCER BIOMARKERS AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 15/828084 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15828084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13856851 [patent_doc_number] => 10190137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => CRISPR-related methods and compositions with governing gRNAS [patent_app_type] => utility [patent_app_number] => 15/825616 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 15 [patent_no_of_words] => 100470 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15825616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12729667 [patent_doc_number] => 20180135056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => DELIVERY OF THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 15/824793 [patent_app_country] => US [patent_app_date] => 2017-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15824793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15039221 [patent_doc_number] => 20190330615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => METHODS FOR MODULATING RNA SPLICING [patent_app_type] => utility [patent_app_number] => 16/463775 [patent_app_country] => US [patent_app_date] => 2017-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16463775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590717 [patent_doc_number] => 20180346907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 15/822692 [patent_app_country] => US [patent_app_date] => 2017-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15822692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14930493 [patent_doc_number] => 20190300884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => MODULATORS OF HUMAN KAI1 METASTASIS SUPPRESSOR GENE, METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/461941 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300787 [patent_doc_number] => 20180201930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS [patent_app_type] => utility [patent_app_number] => 15/809234 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17937083 [patent_doc_number] => 11471515 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Restoration of tumor suppression using MRNA-based delivery system [patent_app_type] => utility [patent_app_number] => 16/348383 [patent_app_country] => US [patent_app_date] => 2017-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 58 [patent_no_of_words] => 26412 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14747349 [patent_doc_number] => 20190256848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => ANTISENSE OLIGOMERS TARGETING HOXB-AS3 LONG NON-CODING RNA [patent_app_type] => utility [patent_app_number] => 16/347311 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702136 [patent_doc_number] => 20180125878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => CONTINUOUSLY EXPRESSED THERAPEUTIC RNAS FOR TARGETED PROTEIN BINDING AND METHODS FOR THEIR USE [patent_app_type] => utility [patent_app_number] => 15/800836 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15800836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15356011 [patent_doc_number] => 10526608 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => In vitro selection of formaldehyde cross-linking aptamers [patent_app_type] => utility [patent_app_number] => 15/797782 [patent_app_country] => US [patent_app_date] => 2017-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 28 [patent_no_of_words] => 15178 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15797782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185734 [patent_doc_number] => 20180044669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/794643 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28887 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15794643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178954 [patent_doc_number] => 20180037891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'TREATMENT OF NANOG RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NANOG' [patent_app_type] => utility [patent_app_number] => 15/791947 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26713 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15791947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13899129 [patent_doc_number] => 20190038769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => MICRO-RNA PROFILING, COMPOSITIONS, AND METHODS OF TREATING DISEASES [patent_app_type] => utility [patent_app_number] => 15/791127 [patent_app_country] => US [patent_app_date] => 2017-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15791127 [rel_patent_id] =>[rel_patent_doc_number] =>)